Chengdu Olymvax Biopharmaceuticals Future Growth
Future criteria checks 5/6
Chengdu Olymvax Biopharmaceuticals is forecast to grow earnings and revenue by 74.3% and 31.6% per annum respectively. EPS is expected to grow by 74.4% per annum. Return on equity is forecast to be 13.4% in 3 years.
Key information
74.3%
Earnings growth rate
74.4%
EPS growth rate
Biotechs earnings growth | 33.7% |
Revenue growth rate | 31.6% |
Future return on equity | 13.4% |
Analyst coverage | Low |
Last updated | 30 Apr 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,067 | 172 | 61 | 123 | 1 |
12/31/2025 | 1,079 | 153 | -27 | 100 | 3 |
12/31/2024 | 658 | 79 | -7 | 65 | 1 |
3/31/2024 | 500 | -12 | -175 | 12 | N/A |
12/31/2023 | 496 | 18 | -126 | 44 | N/A |
9/30/2023 | 529 | 17 | -95 | 93 | N/A |
6/30/2023 | 548 | 24 | -205 | -11 | N/A |
3/31/2023 | 561 | 37 | -206 | -15 | N/A |
12/31/2022 | 547 | 27 | -225 | -25 | N/A |
9/30/2022 | 573 | 70 | -191 | -98 | N/A |
6/30/2022 | 551 | 97 | -95 | 13 | N/A |
3/31/2022 | 477 | 81 | -68 | 17 | N/A |
12/31/2021 | 487 | 108 | -30 | 40 | N/A |
9/30/2021 | 405 | 78 | -22 | 44 | N/A |
6/30/2021 | 378 | 65 | -18 | 21 | N/A |
3/31/2021 | 328 | 50 | -38 | 4 | N/A |
12/31/2020 | 320 | 36 | -18 | 21 | N/A |
12/31/2019 | 179 | -31 | -71 | -42 | N/A |
12/31/2018 | 76 | -19 | -35 | -17 | N/A |
6/30/2018 | 63 | 14 | -32 | -14 | N/A |
3/31/2018 | 54 | 7 | -25 | -8 | N/A |
12/31/2017 | 45 | 1 | N/A | -2 | N/A |
9/30/2017 | 26 | -23 | N/A | -21 | N/A |
6/30/2017 | 7 | -48 | N/A | -40 | N/A |
3/31/2017 | 4 | -52 | N/A | -41 | N/A |
12/31/2016 | 0 | -56 | N/A | -43 | N/A |
9/30/2016 | 0 | -51 | N/A | -37 | N/A |
6/30/2016 | 0 | -47 | N/A | -32 | N/A |
3/31/2016 | 0 | -50 | N/A | -29 | N/A |
12/31/2015 | 0 | -52 | N/A | -27 | N/A |
12/31/2014 | 0 | -30 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688319 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688319 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688319 is expected to become profitable in the next 3 years.
Revenue vs Market: 688319's revenue (31.6% per year) is forecast to grow faster than the CN market (14.7% per year).
High Growth Revenue: 688319's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (13.4%).